-
公开(公告)号：US11155592B2
公开(公告)日：2021-10-26
申请号：US16665072
申请日：2019-10-28
IPC分类号： A61K38/00 , C07K14/575 , A61P3/04 , A61K9/00 , A61K45/06
摘要： PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
-
公开(公告)号：US11242370B2
公开(公告)日：2022-02-08
申请号：US16835787
申请日：2020-03-31
IPC分类号： C07K14/475 , A61P9/04 , A61K38/00 , A61M5/142
摘要： The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
-
公开(公告)号：US20240209055A1
公开(公告)日：2024-06-27
申请号：US18484451
申请日：2023-10-11
IPC分类号： C07K14/575 , A61K9/00 , A61K38/00 , A61K45/06 , A61P3/04
CPC分类号： C07K14/57545 , A61P3/04 , A61K9/0053 , A61K38/00 , A61K45/06
摘要： PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
-
公开(公告)号：US20220112255A1
公开(公告)日：2022-04-14
申请号：US17559430
申请日：2021-12-22
IPC分类号： C07K14/475 , A61P9/04
摘要： The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.
-
公开(公告)号：US20220025009A1
公开(公告)日：2022-01-27
申请号：US17494394
申请日：2021-10-05
IPC分类号： C07K14/575 , A61P3/04
摘要： PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
-
公开(公告)号：US11820803B2
公开(公告)日：2023-11-21
申请号：US17494394
申请日：2021-10-05
IPC分类号： A61K38/00 , C07K14/575 , A61P3/04 , A61K9/00 , A61K45/06
CPC分类号： C07K14/57545 , A61P3/04 , A61K9/0053 , A61K38/00 , A61K45/06
摘要： PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.019 秒)
